Waldenström Macroglobulinemia Clinical Trials
The study’s central analytical question was whether sibling cases are biologically distinct from sporadic ones.
A single-institution series of five sibling pairs (ten patients) with Waldenström’s macroglobulinemia was examined over a 25‑year period. Clinical and laboratory characteristics of familial cases were found to match those of sporadic cases, but overall survival appeared longer in the familial group, suggesting a potential survival advantage or lead‑time bias. The study highlights the importance of familial screening and early detection.
Demonstrating that familial and sporadic Waldenström’s macroglobulinemia share equivalent clinical features implies that family history should be actively probed, and routine IgM screening of siblings could enable earlier diagnosis and improved outcomes.
Bizonyítékszint: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Kapcsolódó jelek
- European Consortium for Waldenström's Macroglobulinemia
- Waldenström Macroglobulinemia - A State-of-the-Art Review: Part 2- Focus on Therapy
- The therapeutic perspective of relapsed/refractory Waldenström Macroglobulinemia: what comes next?
- Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia
- Waldenstrom's Macroglobulinemia Clinical Trials and Research | Dana‑Farber Cancer Institute